石四药(2005.HK)涨5%盘前现大手成交涉资1.38亿港元
格隆汇7月23日丨昨日收报7.01港元的石四药(2005.HK)于9点录得一手2000万股的市前交易,成交价为6.91港元(较上一交易日收市价跌1.43%),涉资1.38亿港元。该股现报7.36港元,涨4.99%,创逾2个月新高,暂成交1.52亿港元,最新总市值223亿港元。

石四药自7月15日开始至今股价整体呈明显上涨走势。7月15日,一份流传出的4+7药品集中采购座谈会纪要透露,第二轮招标品种仍是先前的25个,但招标的范围要从4+7城市拓展到全国所有省份及地区,包括全部地区的公立医院、定点民营医院、军队医院。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.